| 主权项 |
1. A method of treating multiple myeloma in a subject in need thereof comprising administering to said subject an insulin-like growth factor receptor-1 (IGF-1R) inhibitor, wherein said IGF-1R inhibitor is a compound of formula I, wherein:
each W1 through W4 is independently a carbon atom or a nitrogen atom, wherein one of W1-W4 is nitrogen, and W5 and W6 are carbon, with the proviso that when any W1 through W4 is N, then the corresponding substituent(s) X1 through X4 is (are) absent;each X1 through X3 is independently selected from hydrogen, hydroxy, halogen, lower alkyl, lower alkoxy, haloalkyl, trifluoromethyl, nitro, cyano, primary, secondary or tertiary amino;each X5 and X6 is independently selected from hydrogen and lower alkyl;X4 is selected from hydrogen, halogen, or is selected from the following groups: wherein: m is an integer from 1 to 4, and n is an integer from 0 to 4; R2 is selected from optionally substituted aryl, heteroaryl wherein said heteroaryl is imidazoyl, pyridinyl, benzo-dioxanyl, benzo-dioxolyl, benzo-imidazolyl or indolyl, or —(CH2)p-M1-aryl, substituted by substituents independently selected from a group consisting of hydrogen, lower alkoxy, aryloxy, benzyloxy, alkylthio, hydroxy, halogen, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, lower alkyl, lower alkenyl, methylenedioxy, trimethylene, cyano, nitro, tertiary amino, such as dimethylamino, carboxamide, lower alkylsulfonyl, lower alkylthio, optionally substituted aryl or heteroaryl, wherein M1 is O, S, and p is an integer between 0 and 4; R3 is selected from optionally substituted aryl, heteroaryl, wherein the heteroaryl is imidazoyl, pyridinyl, benzo-dioxanyl, benzo-imidazolyl or indolyl, —(CH2)o-aryl, or —(CH2)o— heteroaryl, substituted by a substituent independently selected from a group consisting of hydrogen, lower alkoxy, hydroxy, halogen, trifluoromethyl, trifluoromethoxy, lower alkyl, cyano, nitro, primary, secondary or tertiary amino, carboxamide, optionally substituted aryl or heteroaryl, wherein o is 0 to 5; Y1 is Y2 is wherein: r is 1; and R1 is independently selected from optionally substituted nitrogen containing heterocyclyl; nitrogen containing heterocyclylalkyl; wherein said heterocyclyl and heterocyclylalkyl are piperidinyl, pyrrolidinyl, piperazinyl, azetidinyl, morpholinyl, or quinucleodinyl; and nitrogen containing heteroarylalkyl, wherein substitutions are selected from: hydrogen, lower alkyl, hydroxy, lower alkoxy, amino, di-(lower alkyl)aminoalkyl carboxamido, sulfonamido, SO2-alkyl, SO-alkyl, CO-alkyl, CO2-alkyl, cyano, cyanoalkyl, ketoalkyl, and methanesulfonylalkyl, or a pharmaceutically acceptable salt thereof. |
